News

The conference will focus on the full breadth of commercialization strategies and operations.

Acquisition includes company’s inflammatory disease medicines.

Purchase allows company to provide a fully integrated small-to-medium scale sterile injectable service offering for the biopharma industry.

Boehringer Ingelheim’s unbranded adalimumab-adbm biosimilar will be available at an 81% discount to adalimumab (Humira).

The newly established business under Advent International and Warburg Pincus will be named Simtra BioPharma Solutions.

Exec joins the organization with decades of biopharma experience.

Statistics shows it up 1.5%, representing first annual growth since February 2022

Pharmaceutical product distributor continues goal of delivering safe and affordable medication to patients.

CTDMO is reportedly the first to provide this aforementioned service, which spans through commercialization.

Abrysvo reportedly reduces risk of condition in baby by 57% in the first six months after birth.

CDMO purchases branded sachet-packaging machine for commercial manufacturing.

The insulated shipping containers can be used in the pharma industry and are reportedly environmentally friendly.

This would signify an 8.3% CAGR over the next five years.

Company brings aboard former Pfizer exec as life sciences COO in effort to help further improve patient outcomes.

An analysis by 3 Axis Advisors has found that there is a large variability in pharmacy reimbursement of prescription drugs depending on PBM contracts with insurers. This creates a system with huge inconsistencies on the prices of both generics and branded products.

Project to focus on improving access to EstroGel.

Deal to focus on development and commercialization in key emerging countries.

Deal aims to provide diabetes treatment to patients across the continent.

Nearly 96% of respondents say that this is an issue affecting their respective pharmacy.

Expansion is expected to meet the growing market demand from the region.

Collaboration aims to cut medication costs for patients with conditions ranging from high blood pressure to diabetes.

The program to facilitate engagement between HCPs, industry, and regulatory bodies.

Deal aims to provide diabetes treatment to patients across the continent.

SaaS’ branded platform expected to help grow manufacturer’s therapeutic development processes.

CDMO will continue to produce commercial antibody cancer drug substance, featuring a new $242 million agreement.

The draft guidance document discusses the development of labeling for proposed biosimilars and interchangeable biosimilars for submission under section 351(k) of the Public Health Service Act.

PBM transparency and data reporting requirements are likely to be part of a larger healthcare bill that Congress will work on this fall.

Protective case manufacturer hires James Curleigh, as company prepares to further innovation and expand.